NatureNews.com: Therapeutic HIV vaccines show promise
"Normal vaccines are designed to prevent infections, but so far none has worked for HIV. Therapeutic vaccines, in contrast, aim to treat infected people — in the case of HIV, by boosting ravaged immune systems. Initial clinical trials in the 1990s were disappointing, however, and the vaccines fell from scientific fashion."
To see the full article on nature.com, click here
July 26, 2010
Importance of Therapeutic HIV Vaccine
Conversation with Carl Diffenbach after the Internationa AIDS conference.
July 26, 2010
GI in the Hungarian TV (M1) - "Ma Reggel"
July 26, 2010
DermaVir in Figyelő (Observer) business magazine
A hungarian article in Figyelő (Observer) business magazine was released about the DermaVir Patch. To see the full article click here
July 23, 2010
Medical News TODAY: Some coverage from the NAPWA Symposium - XVIII International AIDS Conference
New data presented by researchers at the XVIII International AIDS Conference this week shows significant momentum for the emerging field of therapeutic vaccines, immune hyperactivation, and other immune based therapies, according to officials from National Association of People with AIDS (NAPWA) and The AIDS Institute, two of the leading USA-based patient advocacy organizations. The data were presented at a special community forum, titled "Research Advances from Therapeutic Vaccines and Other Immune-Based Therapies."
(for the full story on Medical News TODAY click here)
July 22, 2010
"Next Generation" HIV/AIDS Treatments Featured in NAPWA and The AIDS Institute's Community Forum at XVIII International AIDS Conference
Four Therapeutic Vaccines Show Efficacy; Other Leading Therapeutic HIV Vaccines, Anti-Immune Hyperactivation, and Immune-Based Therapies Hit Milestones
(Vienna, Austria 22 July 2010) New data presented by researchers at the XVIII International AIDS Conference this week shows significant momentum for the emerging field of therapeutic vaccines, immune hyperactivation, and other immune based therapies, according to officials from National Association of People with AIDS (NAPWA) and The AIDS Institute, two of the leading USA-based patient advocacy organizations. The data were presented at a special community forum, titled “Research Advances from Therapeutic Vaccines and Other Immune-Based Therapies...
(for more information please click here or to download the Press Release with the Key Developments Backgrounder click here).
July 13, 2010
In Vienna for NAPWA
NAPWA released: Research Advances from Therapeutic HIV Vaccines and
Other Immune-Based Therapies” to be Showcased at NAPWA Sponsored
Community Treatment Research Forum at XVIII World AIDS Conference
To download the Press Release click here or read here the article on MarketWire.
June 12, 2010
Genetic Immunity in the next round of CEVF
Genetic Immunity was selected as one of the top ten companies at the Central European Venture Forum 2010 in Budapest.
The company presented its project to develop DermaVir therapeutic vaccine against HIV/AIDS for the market. The product has just finished phase II clinical trials and showed excellent safety, tolerability and treatment efficacy in HIV+ individuals. The data will be presented at AIDS International 18-23 July, 2010 in Vienna, Austria.
Genetic Immunity received a free ticket to present at the European Venture Summit (EVS) held on 6-7 December 2010 in Düsseldorf, Germany and also qualified for the EVC 2010 Top 100 companies from which experts will select the top 25 most innovative companies who will be given the opportunity to present and compete at The Final Jury & Award Ceremony in Spain, in December 2010.
The presentation of the company received higher scores than the average for every individual point of business consideration.
"We are very proud of these results achieved in a highly competitive field and awarded by top level international business and investment experts." – said Zsolt Lisziewicz, the COO of Genetic Immunity.
The European Foundation for Clinical Nanomedicine (CLINAM) will hold its next conference in May in Basel. It is a very prestigious conference of the European Nanomedicine Society, Julianna Lisziewicz will also give an oral presentation. Registration and abstract submission is still open, please see the call and the preliminary program. (www.clinam.org)
April 29, 2010
The 1st therapeutic vaccine against prostate cancer is approved by FDA.
SEATTLE, April 29, 2010 /PRNewswire via COMTEX/ --Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) has approved PROVENGE(R) (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer (CRPC). PROVENGE is designed to induce an immune response against prostatic acid phosphatase (PAP), an antigen expressed in most prostate cancers, and is the first in a new therapeutic class known as autologous cellular immunotherapies... (for the full article please
click here.)
April 07, 2010
GI in the "alkotonok.hu"
Dr Julianna Lisziewicz CEO of GI, gave an interview to "alkotonok.hu" online magazin. To read the full article - also in english and german -
click here.
AIDS: Therapeutic vaccine "in four or five years" says Montagnier in EP
Last year French Professor Luc Montagnier jointly won the Nobel Prize for Medicine with Françoise Barré-Sinoussi for their discovery of the HIV virus in 1983. On 1 April he took part in a conference on biomedical research organised by the European Parliament. In an exclusive interview we spoke to him about his hopes for a therapeutic vaccine for AIDS sufferers within "four or five years". He also spoke of his worries about a lack of interest in scientific research by young people.
(Click here to continue...)
April 17, 2009
Genetic Immunity's approach appeared in Datamonitor Report.
A large report on vaccine delivery technologies, in which Genetic Immunity’s approach is also introduced appeared in Datamonitor Report in April 2009.
(Click here to see the reference.)
Healthcare division of Datamonitor is an international premium business information and analysis firm based in London. They produce analysis for pharmaceutical and biotech companies as well as other stakeholders on all areas of the healthcare industry, providing data, commentary and market insight. They are an independent and unbiased information provider and not commissioned for their research projects by any particular company.
Febuary 21, 2009
GI in the "Delta" - weekly Hungarian scientific document series.
Documentary on Genetic Immunity's research, development and clinical program.
Genetic Immunity at the finishline. Genetic Immunity's phase II clinical trial conducted at three German clinics will be finished in 2009.
(Click here to read the full article...)
Febuary 03, 2009
GI in the "NOL" "Népszabadság Online" - a national daily newspaper in Hungary
A small interview ' supported with an article and voting option - was done in the internet radio "100 Csoda" about the DermaVir Patch. (Click here to read/hear the full article...)
January 19, 2009
GI reference in "Die Welt" - a national daily newspaper in Germany
January 2009: GI in the Italian magazine Capital: a monthly magazine for businessmen
"She left competitive sport and devoted to genetics. In a short time, she founded a model company specialized in the research on serious diseases starting from scratch. And now Julianna Lisziewicz, President of Genetic Immunity, explains that future is the nanomedicine." (Click here to download the full article...)
January 18, 2009
Biopharmaceutical Innovation Potential: What can be done to accelerate AIDS vaccine research and development?
Europe's significant scientific capacity could prove pivotal in the quest for an AIDS vaccine. However, key challenges, including a translational research gap, must be addressed to best harness Europe's expertise. Download full article
December 06, 2008
Reuters - Nobel winner sees end to AIDS spread within years
STOCKHOLM (Reuters) - A French scientist who shared this year's Nobel prize for medicine said on Saturday he believed the transmission of AIDS could be eliminated within years... full article of Reuters
December 06, 2008
GI in DELTA the Hungarian Scientific Documentary Series
In this program there is a report with Julianna Lisziewicz, CEO of Genetic Immunity about HIV as one of the Scientific Nobel Price winner discoveries in 2008.
The author of the article published in HVG and Napigazdas&aacue;g-Online is Julianna Lisziewicz, CEO of Genetic Immunity. See the full article of HVG, and full article of NapiOnline.
October 23, 2008
Dr Julianna Lisziewicz, president of Genetic Immunity gave a Plenary Lecture at the 2nd Europe INNOVA Conference
Dr Julianna Lisziewicz, president of Genetic Immunity gave a Plenary Lecture at the 2nd Europe INNOVA Conference is organized by the French Presidency of the European Union in close collaboration with the European Commission (DG Enterprise & Industry) and hosted by the city of Lyon. The conference addressed policy priorities for accelerating innovation in Europe with particular focus on the role of research-driven innovation and knowledge transfer, the role of strategic partnerships in strengthening industry's innovation capacity and the mechanisms for supporting innovative SMEs and entrepreneurs. Go to homepage of INNOVA Conference... or Download the presentation (in PDF format)
July 13, 2008
Genetic Immunity to Present at 2008 BIO International Convention
The Forbes and other important media reported about Genetic Immunity to present at 2008 BIO International Convention. See the articles below: Forbes (06.13.08) - 2008 BIO International Convention Exhibitor Profiles, Forbes (06.12.08), Reuters (06.12.08).
April 21, 2008
Full viral suppression newest trend seen in the "post-HAART" era
New immunotherapy treatment could help with trend. In what might be called the post-HAART era, there is an encouraging new trend of clinicans seein greater numbers of patients who have undetectable viral lodas, according to an HIV clinican who has been in the trenches for over two decades. (Continued here...)
April 18, 2008
GI Published Data Related to the DermaVir NanomMedicine Patch in the Journal of Immunology
Genetic Immunity Published Data Related to the DermaVir Nanomedicine Patch in the Journal of Immunology: Data Supports Use of HIV-specific T cell Precursors with High Proliferative Capacity (PHPC) Marker to Predict Reduction of Viral Load. Blood cells from 32 participants were evaluated via a novel PHPC assay as well as a ELISPOT assay to determine which responses correlate with viral suppression and positive immunologic outcomes. The study indicated that a high magnitude of HIV-specific T cell Precursors with High Proliferative Capacity (PHPC), rather than ELISPOT responses, significantly correlated with low plasma viral loads and is therefore an effective diagnostic measurement for determining which responses correlate with viral suppression and positive immunologic outcomes. In contrast to PHPC, which identifies precursor T-cells with high proliferative capacity, ELISPOT is commonly used to monitor immune responses in humans and animals by identifying effector T-cells with low proliferative capacity.
January 24 2008 Genetic Immunity inaugurated its new office and laboratory facility located in Budapest Berlini street... Dr. Lisziewicz the CEO of Genetic Immunity noted the journey of the project during the past 10 years “from the Berlin Patient to the Berlin street”. Genetic Immunity has developing immune therapies inspired by an exceptional clinical observation of the Berlin Patient (Lisziewicz at al. New England Journal of Medicine 1999). The facility is the new home for chemistry, biology and molecular biology laboratories required for research and immune therapy product development. DermaVir Patch quality assurance and control studies will also be performed here in the qualified laboratories and product will be released worldwide to clinical trials. Product and clinical development process is supported by an experienced bio-Information Technology (bio-IT) team, a structure what is unique in this emerging biopharmaceutical industry. The office facility is the center for the Company’s executive management team as well as the international clinical development team.
January 22, 2008
GI on BioData Forum in Geneva
Zsolt Lisziewicz, Chief Operating Officer of Genetic Immunity is invited as speaker to the BioData Forum in Geneva (Visit website: www.biodataforum.com)
October 11, 2007
GI in the BioWorld Today
BioWorld Today: "Genetic Immunity LLC, of New York, has completed a $2 million bridge financing. Terms of the financing were not disclosed. The funds will be used to launch an additional Phase II proof-of-concept trial for the DermaVir Patch, the company's product for reconstituting the viral load in HIV-positive people."
September 28, 2007
"GlaxoSmithKline cancer vaccine 'impressive'" published by DrugResearcher.com
September 21, 2007
"Statement: Immunizations Are Discontinued in Two HIV Vaccine Trials" published by NIH.
"Nanochemistry-Based Immunotherapy for HIV-1" is the new article of Prof. Julianna Lisziewicz. She is publishing in the Bentham Science Publishers. Download the article click here.
August 07, 2007
FDA approves new AIDS drug - can read the article on the USA Today webpage: www.usatoday.com
July 18, 2007
Dr. Julianna Lisziewicz, Chair of the Vaccine Therapy Cluster, is invited as speaker on the 15th International Congress of the Hungarian Society of Microbiology which will take place on July 18 - 20 in Budapest (Download: Program of Congress and Second Circular and General info. Or visit website: www.mmt.org.hu)
July 14, 2007
Quality scientific publications in Dermatology Open Journals (Bentham Scientific Publishers) See in details...
June 25, 2007
The European Commission has published the second FP7 call for proposals. Identifier: FP7-HEALTH-2007-B Publication date: 19 June 2007 Deadline: 18 September 2007 at 17:00:00 (Brussels local time) OJ Reference:OJ C135 of 19 June 2007 Additional information on the Health research call can be found under cordis.europa.eu
June 12, 2007
The following articles have been published about the "1st International Symposium on Genetic and Immune Correlates of HIV Infection and Vaccine-Induced Immunity" conference: VG.hu, Origo.hu, Pride.hu, Hirado.hu, WebOrvos.hu, Pozitiv.org.hu, www.masok.hu, hivpozitiv.extra.hu, www.medimagister.hu.
June 12, 2007
1st International Symposium on Genetic and Immune Correlates of HIV Infection and Vaccine-Induced Immunity 10-13 June, 2007. Budapest, Hungary. VTC (J. Lisziewicz) and Semmelweis University (G. Füst) are coorganizing the conference. For more information visit page www.diamond-congress.hu/hiv2007
May 19, 2007
Interview on NPR with Dr. Anthony Fauci on the progress on prophylactic HIV vaccines Listen the interview here...
April 16, 2007
Zsolt Lisziewicz and Csilla Nemes of Genetic Immunity have attended at Semmering Conference 2007. hosted by Vienna Vaccines.
March 09, 2007
Article entitled "Magyarországra még vár a tudomány, de kire vár Magyarország?" has been published in magyaronline.net. Click here to read the article.
January 22, 2007
Recommendation of the Parliamentary Assembly of the Council of Europe: "...address the development and testing of medicines specifically for use in children living with HIV, and new technologies such as microbicides and HIV/AIDS vaccines" (click here...)
November 22, 2006
Intensive workshop on the project and on future progress of the atherosclerosis group (Programme)
November 10, 2006
On invitation of Prof. Julianna Lisziewicz Dr. Arya Suresh from USA visited us and held a successful seminar (Source)
In the monthly publication of Semmelweis University Kata Tolnai reported about the VTC cluster (source: Semmelweis Egyetem újság 2006/7.)
June 12, 2006
Dr. Julianna Lisziewicz, Chair of the Vaccine Therapy Cluster is invited as speaker to the AIDS Vaccine 2006 Conference which will take place on August 29 - September 1, 2006 in Amsterdam, The Netherlands. Her presentation title is "DermaVir patch therapeutic vaccine in chronic HIV infection: from the concept to the clinic". And the reaction:
June 12, 2006
Dr. Zsolt Lisziewicz, CEO of Genetic Immunity Kft. is invited to the Life Sciences Partnering China & Europe Programme which will take place on Sept. 18-19 in Beijing, China. Meetings with chinese vaccine development companies and leading CDC (Center of Desease Control) officers are planned as well.
June 12, 2006
Eszter Berzsenyi of Genetic Immunity starts one week visit to RIGHT Italy. She will work under the supervision of Prof. Franco Lori. The goal of her trip is to learn the biological assays characterizing the DermaVir Patch product and transfer these assays to the new Budapest laboratories of Genetic Immunity.
May 30, 2006
Prof. Julianna Lisziewicz, the leader of the Vaccine Therapy Cluster, has visited IATEC in Amsterdam to establish collaboration.
May 26, 2006
Prof. Julianna Lisziewicz, the leader of the Vaccine Therapy Cluster, has visited RIGHT to oversee the collaborative research progress between Genetic Immunity and RIGHT.
May 24, 2006
Prof. Julianna Lisziewicz, the leader of the Vaccine Therapy Cluster, has visited Karolinska Institute in Stockholm to establish collaboration.
May 17, 2006
The Second Management Committee Meeting took place in the Chemical Research Center, Budapest. There was discussion about the scientific progress, the patent and process development issues, ISO operating procedures. CRC team leaders presented excellent progress in vaccine chemistry. Leaders of VTC with Solvo defined the short, medium and long-term business development focus.
May 02, 2006
Dr. Eszter Ujhelyi of St Laszlo Hospital starts one week visit to RIGHT Italy. She will work under the supervision of Prof Franco Lori and Dr. Sandra Calarotta. The goal of her visit is to learn the ELISPOT and Cultured-ELISPOT assay and establish these assays in the clinical immune diagnostic laboratory of Laszlo Hospital.
